The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Karyopharm Therapeutics Inc shares valued at $3,172 were sold by Paulson Richard A. on Oct 04 ’24. At $0.88 per share, Paulson Richard A. sold 3,607 shares. The insider’s holdings dropped to 1,135,607 shares worth approximately $1.12 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Mano Michael sold 3,971 shares, netting a total of over 2,866 in proceeds. Following the sale of shares at $0.72 each, the insider now holds 273,881 shares.
Before that, Paulson Richard A. had sold 3,667 shares from its account. In a trade valued at $2,647, the President and CEO traded Karyopharm Therapeutics Inc shares for $0.72 each. Upon closing the transaction, the insider’s holdings decreased to 3,667 shares, worth approximately $1.13 million.
As published in their initiating research note from Piper Sandler on January 19, 2023, Karyopharm Therapeutics Inc [KPTI] has been an Overweight and the price target has been revised to $8. Analysts at RBC Capital Mkts upgraded the stock from ‘”a Sector perform”‘ to ‘”an Outperform”‘ outlook in a report released in early November. As of February 09, 2022, JP Morgan has increased its “an Underweight” rating to a “Neutral” for KPTI.
Analyzing KPTI Stock Performance
During the last five days, there has been a surge of approximately 21.30%. Over the course of the year, Karyopharm Therapeutics Inc shares have jumped approximately 14.43%. Shares of the company reached a 52-week high of $1.9500 on 02/06/24 and a 52-week low of $0.6555 on 01/16/24. A 50-day SMA is recorded $0.8004, while a 200-day SMA reached $1.0230. Nevertheless, trading volume fell to 8.36 million shares from 0.35 million shares the previous day.
Support And Resistance Levels for Karyopharm Therapeutics Inc (KPTI)
According to the 24-hour chart, there is a support level at 0.8633, which, if violated, would cause prices to drop to 0.7367. In the upper region, resistance lies at 1.1232. The next price resistance is at 1.2565. RSI (Relative Strength Index) is 67.16 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.0330, which suggests the price will decrease in the coming days. Percent R is at 44.21%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
